Evaluation of Antibody Response After Vaccination with Inactivated SARS-CoV-2 Vaccine in Health Workers
COVID-19, which emerged in Wuhan in December 2019 and spread all over the world, is an infectious disease. Vaccine studies have been started rapidly by many centers. One of them is the inactive CoronaVac vaccine of Sinovac Company. Turkey has given approval for the emergency use of CoronaVac. In thi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2021-06-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://floradergisi.org/managete/fu_folder/2021-02/338-343%20ismail%20Davarci.pdf |
| Summary: | COVID-19, which emerged in Wuhan in December 2019 and spread all over the world, is an infectious disease. Vaccine studies have been started rapidly by many centers. One of them is the inactive CoronaVac vaccine of Sinovac Company. Turkey has given approval for the emergency use of CoronaVac. In this study, it was aimed to investigate the antibody responses to the vaccine in health workers who work in high-risk departments for COVID-19 in our university and are vaccinated with CoronaVac. Health workers participating in the study were divided into the vaccine group and control group. Forty-one people from the vaccine group and 12 people from the control group volunteered to our study. The vaccine and control group samples taken 14 days after the first dose of vaccine were studied with anti SARSCoV-2 IgG (Euroimmun, Germany). The antibody levels of four people in the vaccine group could not be examined after the second dose of vaccine due to reasons such as resignation and annual permit. Antibody levels were not measured in the control group after the second dose of vaccine. The antibody level after the first dose was found to be 9.8% and 0% in the vaccine group and control group, respectively. After the second dose of the vaccine, this rate was found to be 94.6% in the vaccine group. Based on the current findings, it is thought that a single dose of the vaccine cannot produce an antibody response at the desired rate in the study group, and it is essential to comply with personal protection rules until social immunity reaches the desired levels. |
|---|---|
| ISSN: | 1300-932X 1300-932X |